Innovation & Technology Transfer unit

Transcription

1 September 2009 Innovation & Technology Transfer unit Fundació Clínic, Hospital Clínic de Barcelona

2 Contents Introduction to Hospital Clínic de Barcelona Functional Innovation Unit Technology offers Clinical trials 2/27

3 Hospital Clinic Barcelona Public Hospital. 850 beds, Opened in 1906 and transferred to the Government of Catalonia in January 2008, with a new Governance Board Chaired by the Consellera de Salut (Health Minister of Catalonia ) Two buildings in the center of Barcelona (Eixample and Les Corts), With long R&D tradition, and a drive for innovation. Top academic teaching hospital linked to Barcelona University Rich networking with public and private institutions 3/27

4 It is a health care institution, with long biomedical research expertise CSC Gesclínic S.A. Hospital Clínic Hospital Maternity Home TSF Barna Clínic FCRB IDIBAPS CRESIB Primary care Hospital Other Biomedical Companies Research and Development 4/27

5 Research and Innovation the Biomedical Research Institute August Pi i Sunyer (IDIBAPS) and Research Center of International Healtcare of Barcelona (CRESIB) were founded in order to integrate high quality clinical research with high level basic research. Hospital Clínic UB Medical University IIBB (CSIC) Generalitat de Catalunya Generalitat de Catalunya (Health Dep. ) Generalitat de Catalunya (DEU) University of Barcelona Hospital Clínic IDIBAPS IDIBAPS CRESIB Fundació Clínic (FCRB) Fundació Clínic (FCRB) /27

6 Research Researchers > 400 Groups of Res. 55 Resources managed 65 M st accredited centre for the ISCIII Institute for Health Research Hospital Clínic/ IDIBAPS 1 - Biological aggression and response mechanisms 4 Clinical and Experimental Neurosciences 2 - Respiratory, Cardiovascular and Kidney Biopathology and Bioengineering 5 Oncology and Haematology 3 - Liver, Digestive System and Metabolism 6 International Health 6/27

7 RESEARCH AS A STRATEGIC PRIORITY OF THE HCB Research results place the Hospital in a leading position at national level Scientific Production Clínic /IDIBAPs Competitive resources Clínic / IDIBAPS Millions 16,5 23,6 28,5 33,4 38,7 44, Originals Impact Factor P ublic Private Scientific Production of Top Hospitals in Sapin ( ) Hospital Docs Citations C / D H. Clínic de Barcelona ,49 H. Vall d Hebrond ,95 H. Sant Pau ,42 H. Ramón n y Cajal ,06 H. La Paz ,47 7/27

8 El HCB produced the 16% of hospital citations and the 7,38% of all Biomedical Research citations in Spain (period ). 8/27

9 HCB IDIBAPS its competitive at the EU level : European Projects Evolution over time. Financing Partner Líder Total Leadership Leadersip success rate Partner Líder % Líderado % Éxito

10 New research building m2 (building m2) Interconnected HCB-IDIBAPS-UB-FCRB Research Laboratory, Technological Platforms, Biobanks 10/27

11 Contents Introduction to Hospital Clínic de Barcelona Functional Innovation Unit Technology offers Clinical trials 11/27

12 INNOVATION AS STRATEGIC PRIORITY Innovation in a wide sense (products, processes, systems and organization) as a mean to improve: Translational research. Healthcare indicators. End user satisfaction (the patient). Efficiency, with improvements exportable to healthcare system. Impact on the productive sector, specially in Catalonia & Spain Satisfaction of professionals and the capacity to attract, develop and retain top talent. Economic return and improved sustainability of the hospital and healthcare system. 12/27

13 Innovation Unit Innovation unit created at 2006 Professional profiles with industry background Creating innovation culture, defining institutional policies Changing industry-academy approximation, creating value through strategic alliances 13/27

14 Innovation as a transversal function: task force Framed into the research & innovation policy of HCB Director: Joan Bigorra Assessment of Innovation & New Technologies: Laura Sampietro-Colom Strategic Marketing & Business Development: Albert G. Zamora Mireia Angulo Teresa Lloret Yolanda Lizarraga CORE TEAM INNOVATION Knowledge management : Marie Huc Clinical Research Manager : Carlos Lurigados Controller : Gloria Oliver Project Management : Teresa Peña Bioengineering Information Systems Legal Communication Part time dedication to innovation Support to innovation 14/27

15 ASSESSMENT OF INNOVATIONS AND NEW TECHNOLOGIES Identify and evaluate prospective innovations and NT 1 with high interest for the hospital Training in assessment and methodological support / to facilitate the evaluation of high value for HCB 3, Evaluation Networks & Strategic Alliances (National & International) Standardization of the planning and acquisition processes based on the outcome of the evaluation. Hospital 2020, new organizational models 15/27

16 STRATEGIC MARKETING & BUSINESS DEVELOPMENT Intellectual Property Management innovations management / technology transfer - BD/ licensing-collaboration agreements - Starts-Ups (Spin-Offs) Management of companies of new creation (interim management) Strategic alliances and partnerships in innovation (National & International) Consulting services, teaching, co-development of innovation projects 16/27

17 Some examples of strategic alliances Olympus Siemens UDIAT-Telefónica Continua Alliance (with National Health Service and Connected Health Organization of Boston) worldwide reference center in minimally invasive surgery and interventional endoscopy in Gastroenterology, Urology and Gynecology. worldwide reference Center in Molecular Imaging (in vivo-in vitro) Development of Teleradiology Development of programs for chronic illness teleassistance, of digital clinical guidelines and connectivity elements of the electronic medical record. SAP-Accenture Integration platform for different IT systems in Barcelona. 17/27

18 Important increase in patent applications and technology transfer processes Nº of Tech transfer projects Intelectual-Industrial Property/ Patents IP Registers Patent Applications PCT Extensions Total I+D+i HCB Alliances Strategyc Alliances Having access to KOL Assessment in product developments Consultancy & Market Research Licensing & Collaboration Agreements Therapeutics Diagnostics New technologies Monitoring Agreements/Companies Licensing Agreements Spin-Offs 18/27

19 Contents Introduction to Hospital Clínic de Barcelona Functional Innovation Unit Technology offers Clinical trials 19/27

20 Technology Offers We currently have several technologies ready to be offered to industrial partners including medical devices, biomarkers, targets, biologics, etc. Visit our website for more information: a/tabid/892/language/en-us/default.aspx Or contact to Strategic Marketing & Business Development Department: , extension /27

21 Contents Introduction to Hospital Clínic de Barcelona Functional Innovation Unit Technology offers Clinical trials 21/27

22 HOSPITAL CLINIC - CLINICAL TRIALS HCB / FCRB is the first Hospital in Spain conducting Clinical Trials CEIC evaluations by year in HCB 247 in /27

23 SUPPORTING SERVICES FOR CLINICAL TRIALS Clinical Research Manager: Contact person for any issue related with Clinical Trials Phone: Tel. + (34) Ext Investigational Therapy Unit (Inther Unit): A Clinical Trial Unit specific for phase I and II Trials: preferably proof of concept with patients Strategic positioning in haematology and oncology, but not exclusivity Specific supporting Departments for managing: Protocol authorisations; Ethics Committee Contracts Invoices Periodical GCP training for investigators 23/27

24 TOP COUNTRIES IN NUMBER OF SITES FOR CLINICAL TRIALS 1º USA, 2º Germany, 3º France, 4º Canada, 5º UK 6º Spain 7º Italy 24/27

25 CLÍNIC Healthcare corporation Joan Bigorra, Innovation Director Ph Albert G. Zamora, Strategic Mktg & BD Manager Ph

26 1 - Biological aggression and response mechanisms Experimental and clinical toxicology Inflammatory Arthropaties (GRAI) Systemic Autoimmune Diseases Infection diseases and AIDS Immunoreceptors of the innate and adaptative system Epidemiology, public health and international health research group Molecular and cellular basis of inflammation, Structural and biological mass spectrometry 2 - Respiratory, Cardiovascular and Kidney Biopathology and Bioengineering Atherosclerosis, coronary desiease and cardiac insufficiency Electrophysiology Nephrological disease and kidney transplant Hypertension, lipids and cardiovascular risk Management and prevention of infectious, interstitial and tumoral pulmonary diseases Physiopathological mechanisms of respiratory diseases Clinical and experimental respiratory immunoallergy 3 - Liver, Digestive System and Metabolism Ginaecological Endocrinology and Human Reproduction. Foetal and Perinatal Medicine. Metabolic Regulation and Molecular Pathology. Metabolic Bone Disease. Viral Hepatitis in Immunocompetent and Liver Transplanted Patients. Pathophysiology and Treatment of Ascites and Renal Function Disorder in Hepatic Cirrhosis. Hepatic Oncology. Hepatic Haemodynamics and Portal Hypertension. Upper gastrointestinal haemorrhage from ruptured oesophageal varicous veins. Inflammatory Bowel Disease. Hepatic Insufficiency and Cholestasis. Mitochondrial regulation of apoptosis and steatohepatitis. Liver Transplantation and Graft Viability. Gastrointestinal and Pancreatic Oncology. Experimental Diabetes. Cellular and Molecular Research in Experimental Diabetes Models. 26/27

27 4 Clinical and Experimental Neurosciences Experimental Neuropharmacology and Neuropathology. Degenerative and autoimmune diseases of the nervous system. Neurophysiology and functional exploration of the nervous system. Secondary lesions caused by chronic alcohol consumption: muscle pathology Cellular biology of pathological processes. Biological basis of psychic disorder and nuclear psychiatry. Neuropsychology. Neurobiology unit. Cerebral Ischemia: clinical and experimental studies. Molecular neurobiology (virtual Group of IDIBAPS in the Faculty of Biology of UB) 5 Oncology and Haematology Biological markers in oncology. Human and experimental functional oncomorphology. Diagnosis and therapeutics in oncology. Molecular genetics. Genetics Melanoma: Imaging, Genetics and Immunology. Hemopoietic progenitor cell transplantation. Haematooncology. Pathophysiology and molecular basis in haemotology. Haemotherapy haemostasis. 6 International Health Epidemiology, Public Health and International Health Research Group 27/27